AMAG Pharmaceuticals, Inc. (AMAG) Stake Decreased by Jane Street Group LLC

Jane Street Group LLC lessened its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 97.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,273 shares of the specialty pharmaceutical company’s stock after selling 388,727 shares during the quarter. Jane Street Group LLC’s holdings in AMAG Pharmaceuticals were worth $208,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of AMAG. Nordea Investment Management AB raised its position in AMAG Pharmaceuticals by 1.1% in the 2nd quarter. Nordea Investment Management AB now owns 37,200 shares of the specialty pharmaceutical company’s stock valued at $684,000 after purchasing an additional 400 shares during the last quarter. Arizona State Retirement System raised its position in AMAG Pharmaceuticals by 2.2% in the 2nd quarter. Arizona State Retirement System now owns 18,300 shares of the specialty pharmaceutical company’s stock valued at $337,000 after purchasing an additional 400 shares during the last quarter. Teachers Advisors LLC raised its position in AMAG Pharmaceuticals by 0.7% in the 2nd quarter. Teachers Advisors LLC now owns 62,481 shares of the specialty pharmaceutical company’s stock valued at $1,150,000 after purchasing an additional 426 shares during the last quarter. PNC Financial Services Group Inc. raised its position in AMAG Pharmaceuticals by 2.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 18,766 shares of the specialty pharmaceutical company’s stock valued at $346,000 after purchasing an additional 486 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its position in AMAG Pharmaceuticals by 6.6% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after purchasing an additional 510 shares during the last quarter.

AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at $13.87 on Monday. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48. The stock has a market cap of $500.55, a price-to-earnings ratio of -2.28 and a beta of 0.79. AMAG Pharmaceuticals, Inc. has a 12 month low of $11.93 and a 12 month high of $36.60.

AMAG has been the subject of several research reports. Jefferies Group reiterated a “buy” rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research report on Sunday, November 5th. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research report on Wednesday, October 4th. Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Cantor Fitzgerald reiterated a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Finally, Deutsche Bank reiterated a “hold” rating and issued a $24.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, August 31st. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $23.38.

ILLEGAL ACTIVITY WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/12/25/amag-pharmaceuticals-inc-amag-stake-decreased-by-jane-street-group-llc.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

What are top analysts saying about AMAG Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit